Background: KRAS is one of the most frequently mutated oncogenes in human cancers, 22 but its activating mutations have remained undruggable due to its picomolar affinity for GTP/GDP 23 and its smooth protein structure resulting in the absence of known allosteric regulatory sites. 24
replaced with fresh culture medium 24 hours after infection, and the cultures were supplemented 142 with 2 μg/ml puromycin (InvivoGen, ant-pr) and incubating for 48 hours. Subsequently, the double-143 transduced cells were counted and subjected to other assays. 144 T7E1 assay 145 Genomic DNA was isolated using the Genomic DNA Kit (Tiangen, #DP304-03) according to the 146 manufacturer's instructions. The region of DNA containing the nuclease target site was amplified 147 by PCR with the following primers: KRAS forward, 5'-atgcatttttcttaagcgtcgatgg-3'; KRAS reverse, 148 5'-ccctgacatactcccaaggaaag-3'. The PCR amplification was performed according to the following 149 protocol: 2 min at 94 °C; 30 cycles of (10 s at 98 °C, 30 s at 56 °C, 25 s at 68 °C). After separation 150 on a 2% agarose gel, size-selected products were purified using QIAquick Gel Extraction Kit 151 (QIAGEN, 28706) . The purified PCR products were denatured by heating and annealed to form 152 heteroduplex DNA, and then treated with 5 units of T7 endonuclease 1 (New England Biolabs) for 153 30 min at 37°C and finally analyzed by 2% agarose gel electrophoresis. 154
RNA extraction and qPCR 155
Total RNA was isolated from cells using TRIzol LS reagent (Invitrogen, 10296028) following the 156 manufacturer's protocol. One microgram of RNA was then reverse transcribed using Primescript 157 RT Reagent (Takara, RR047A). Quantitative PCR was performed using Fast Sybr Green Master mix 158 (Applied Biosystems) and the primers were: KRAS forward, 5'-atgcatttttcttaagcgtcgatgg-3'; KRAS 159 reverse, 5'-ccctgacatactcccaaggaaag-3'. Each messenger RNA (mRNA) level was measured as a 160 fluorescent signal normalized based on the signal for glyceraldehyde 3-phosphate dehydrogenase 161
Western blot analysis 176 A549 and H2228 cells were plated in six-well plates at a confluent of 70%. 48 hours after adenovirus 177 infection, whole-cell extracts were prepared by lysing cells with adding 500 µL hot SDS-PAGE buffer 178 (Beyotime, P0015B). Tumor tissues were homogenized by TGrinder (Tiangen, OSE-Y30), and lysed 179 with RIPA buffer containing complete protease inhibitor cocktail (Roche). Target proteins were 180 detected by western blot analysis with the following antibodies: GAPDH mouse monoclonal 10 antibody (Proteintech, 60004-1-Ig), Akt (pan) (40D4) mouse monoclonal antibody (Cell Signaling, 182 2920), Phospho-Akt (Ser473) in the abdomens of 6-to 8-week old male NCG mice by subcutaneous injection of A549 (5×10 6 cells 191 in 200 µL DPBS (Gibco, C14190500BT)) or H2228 cells (2× 10 6 cells in 200 µL DPBS). After tumor 192 cell injection, when tumor volumes reached a range of 50-100 mm 3 , mice were randomly 193 separated to one of five groups to receive PBS, AdV-Cas9, AdV-Cas9-sgG12S, KRAB-sgG12S (nine mice per group). The first day of treatment was designated as day 1. PBS, 195 Adenovirus (1 × 10 9 PFU in 10 µL DPBS), or lentivirus (5 × 10 10 copies in 70 µL DPBS) was 196 administered intratumorally on day 1, 4 and 7. Tumor growth inhibition was evaluated twice a week 197 by measuring the length (L) and width (w) of the tumor. Tumor volume was determined using the 198 following formula: volume = 0.523L(w) 2 . 199
H&E staining 200
Formalin-fixed and paraffin-embedded tumor tissues were cut into sections and stained with 201
Tumor tissues were formalin-fixed, paraffin-embedded and stained using anti-RAS (G12S) mouse 204 monoclonal antibody (NewEast, 26186) followed by incubation with HRP-conjugated 205 corresponding secondary antibody (Sigma-Aldrich). The expression levels were evaluated by H-206 score method. Scoring was independently reviewed in parallel by two experienced pathologists. 207
Analysis of off-target effects 208
Paired-end reads of each sample were aligned against the sequence of each off-target locus 209 (~150bp) using BWA-MEM 23 (version 0.7). The mapped reads for each off-target locus were then 210 obtained from the alignment result. Mapped reads number (M) for each off-target locus could be 211 got by using SAMtools idxstats module 24, 25 . By applying a tool called FLASH 26 , the mapped paired-212 end reads were merged. By using regular expression to search the sequences of off-targets' 213 protospacers and their reverse complementarity sequence in the above merged read files, the 214 number of protospacers (S) among the mapped reads could be obtained. The editing efficiency for 215 an off-target could be obtained via the following equation: 216
PAM analysis 218
Annotate and prioritize genomic variants based on previous report 27 . Briefly, use ANNOVAR 28 to 219 annotate COSMIC v88 mutation database (perl table_annovar.pl humandb/hg19_cosmic88.txt 220 humandb/ -buildver hg19 -out cosmic -remove -protocol refGene -operation gx -nastring . -csvout), 12 and select variants located in the exons of the 20 cancer driver genes. Based on the gene mutation 222
and wild-type genome information (https://www.ncbi.nlm.nih.gov/assembly/GCF_000001405.25), 223
we applied Pandas (https://pandas.pydata.org/), a python package, to analyze the COSMIC SNP 224 mutation information to generate a data frame. We applied Pyfaidx 29 , a python package to extract 225 specific sequences from the GRCh37.p13 reference genome. PAM sequences of SpCas9, SaCas9, 226
and LbCpf1 CRISPR nucleases were analyzed in the GRCh37.p13 reference genome. Once the SNP 227 mutation is in the seed region of PAM sequences, we consider it can be edited by CRISPR nucleases. 228
Statistical analysis 229
Significance of all data was determined using two-tailed Student's t-test, and p-values <0.05 were 230 considered statistically significant. 231
Results

232
Cas9-sgG12S specifically targets KRAS mutant alleles 233 KRAS gene locates in the short arm of human chromosome 12. There are four dominant mutant 234 alleles at G12 position in exon 1, G12S (c.34G>A), G12V (c.35G>T), G12C (c.34G>T) and G12D 235 (c.35G>A) ( Figure 1A ). These single nucleotide missense mutations are next to a PAM (TGG) 236 sequence recognized by SpCas9. Since variations of DNA base in the PAM or seed sequence affect 237 the recognition of SpCas9, five sgRNAs in total were designed to target the four KRAS mutant alleles, 238
including G12S (sgG12S), G12V (sgG12V), G12C (sgG12C) and G12D (sgG12D), and the KRAS-WT 239 gene (single guide G12-wild type RNA, sgG12-WT). 240 Figure S .1A) into 293T cells separately. We found that sgG12-WT disrupted KRAS-WT efficiently 244
with an efficiency of 66% by T7E1 assay, while the editing efficiency of sgG12S, sgG12V, sgG12C 245 and sgG12D in KRAS-WT were 3%, 12%, 2% and 15%, respectively ( Figure 1B) . Thus, sgG12S and 246 sgG12C were more specific with much lower off-target effects on wildtype KRAS. Next, we 247 confirmed the editing efficiency of sgG12S in A549 lung adenocarcinoma cells harboring KRAS G12S 248 mutant allele. H2228, another lung adenocarcinoma cell line carrying no G12S mutant allele, was 249 utilized as a negative control. Lentivirus containing spCas9-sgG12S or spCas9-sgG12-WT, and non-250 targeting control virus ( Figure 1C ) were respectively infected into A549 and H2228 cells. We found 251 that spCas9-sgG12S edited KRAS G12S mutant allele in A549 cells with a high efficiency of 89%, 252 while the editing efficiency was only 1% in wild-type KRAS allele in H2228 cells ( Figure 1D ). On the 253 other hand, sgG12-WT edited KRAS in A549 and H2228 cells with editing efficiency of 38% and 82%, 254 respectively, indicating that the sgG12-WT non-specifically bound to KRAS G12S sites with a high 255 mismatch tolerance. To further confirm that sgG12S specifically edited KRAS G12S mutant allele, 256 but not the wild-type allele, KRAS gene in puromycin selected A549 and H2228 cells was sequenced 257 2-3 days post infection ( Figure 1E ). KRAS in A549 was destroyed around PAM (TGG) sequence, while 258 H2228 was not affected, further confirming the success of our spCas9-sgG12S system in efficient 259 and specific targeting KRAS G12S allele ( Figure 1F) . 260
proliferation and cell cycle of tumor cell lines in vitro 262
To investigate whether targeting and disruption of the KRAS mutant allele by sgG12S could inhibit 263 the proliferation of tumor cells, the cell numbers of A549 and H2228 cells were examined after 264 gene editing (Figure 2A ). The proliferation of sgG12S-targeted A549 cells was dramatically inhibited 265 and almost retarded compared to non-targeting control and untreated groups. While the targeting 266 of sgG12S had no effect on the proliferation of H2228 cells. Besides, a cell colony formation assay 267 (CFA) ( Figure 2B ) and CCK-8 cell proliferation assay ( Figure 2C ) also confirmed the growth inhibition 268 by Cas9-sgG12S targeting. As demonstrated in cell counting (Figure 2A ), the proliferation of A549 269 cells was significantly suppressed shown in the CFA and CCK-8 assays. In contrast, the targeting of 270 sgG12S had a less effect on the proliferation of H2228 cells carrying the wild-type KRAS allele. 271
We further assessed the cell cycle of sgG12S-targeted A549 and H2228 cells ( Figure 2D ). The 272
Cas9-sgG12S treated A549 cells was mostly arrested at S phase, and the ratio of cell population at 273 G2/M phase was downregulated correspondingly, while there was no effect on the cell cycle of 274 sgG12S-treated H2228 cells. Next, we examined the activities of KRAS downstream signaling 275 pathways including the expression and activation of AKT and ERK ( Figure 2E ). The treatment of 276
Cas9-sgG12S in A549 tumor cells dramatically suppressed the expression of KRAS (G12S) protein, 277 while the expression of wild-type KRAS protein in H2228 cells were not affected. Besides, the levels 278 of phosphorylated-AKT (S473) and phosphorylated-ERK (T202/Y204) proteins were significantly 279 downregulated in A549 cells edited with SpCas9-sgG12S, while another type of phosphorylated-280 ERK (T183/Y185) protein was not affected. As expected, AKT and ERK signaling pathways in H2228 281 cells were not affected by SpCas9-sgG12S. Collectively, our results suggested that the mutant allele-specific targeting by sgG12S can efficiently inhibit tumor cell proliferation and arrest the cycle of 283 tumor cells at S phase, probably through downregulating AKT and ERK signaling pathways. 284 Transcription-repressing system dCas9-KRAB inhibited 285 proliferation of tumor cell lines in vitro 286 We next explored whether there were off-target effects of the mutant allele-specific nuclease 287 outside of KRAS gene region by targeted deep sequencing at 14 potential off-target sites 288 (Additional file 1: Supplemental Table 1 ). The potential off-target sites which were different from 289 the on-target site by up to 4 nt mismatch in the human genome were identified by Feng Zhang lab's 290 CAS-OFFinder algorithm (http://www.rgenome.net/cas-offinder/). No indel was detected at these 291 sites in Cas9-sgG12S treated A549 and H2228 tumor cells ( Figure 3A, 3B) . 292 Genome-editing system has the likelihood to cause undesired double stand break (DSB) in the 293 genome ( Figure 1B, 1D) . In order to avoid the undesired disruption of genome, we constructed a 294 non-cutting transcription-regulating system, dCas9-KRAB system ( Figure 3C) , where KRAB is a 295 transcriptional repressor to downregulate mRNA expression when binding to the regulatory 296 elements of certain genes 30, 31 . To test whether sgG12S linked to dCas9-KRAB may repress KRAS 297 expression specifically in G12S mutant allele, A549 and H2228 cells were infected by dCas9-KRAB-298 sgG12S and non-targeting control lentivirus. As expected, the transcription of KRAS G12S mutant 299 allele in dCas9-KRAB-sgG12S treated A549 cells was dramatically downregulated compared to non-300 targeting control or untreated cells ( Figure 3D ), while in H2228 cells, the transcription of wild-type 301 KRAS was not affected in all three groups. In addition, the effect on tumor cell growth was also 302 investigated by CCK-8 assay ( Figure 3E ). Consistently, the proliferation of dCas9-KRAB-sgG12S treated A549 cells was inhibited significantly compared to the controls, while no significant effect 304 on H2228 tumor cell growth was observed. These results confirmed the in vitro specificity of the 305 dCas9-KRAB system. 306
Targeting KRAS-G12S mutant blocks tumor growth in 307 tumor-bearing mice 308 To further explore the effects of KRAS-sgG12S targeting in vivo, AdV-Cas9-sgG12S and non-309 targeting control adenovirus were constructed and packaged (Additional file 1: Figure S2A) . 310
Lentivirus is relatively limited to use for in vitro or ex vivo gene delivery due to their restricted 311 insertional capacities and relatively low titers. 32 Therefore, the in vivo gene delivery experiments 312 were conducted by adenoviral infection. The editing efficiency of AdVs was firstly confirmed in 313 A549 and H2228 cells by T7E1 assay (Additional file 1: Figure S2B ) and sanger sequencing 314 (Additional file 1: Figure S2C ). As expected, AdV-Cas9-sgG12S specifically edited KRAS G12S mutant 315 allele in A549 cells, but not in H2228 cells harboring wild-type KRAS gene. In addition, AdV-Cas9-316 sgG12S inhibited the proliferation of A549, but not H2228 tumor cells in vitro (Additional file 1: 317 Figure S2D ). 318
Next, we examined the effect of sgG12S editing in cell-derived xenograft models of A549 and 319 H2228 cells, respectively ( Figure 4A-D) . Local injection of AdV-Cas9-sgG12S significantly inhibited 320 tumor growth, resulting in a 46% reduction in tumor volume (P<0.01) in A549-bearing mice (Figure  321 4A). In contrast, tumor volumes of control groups treated with either PBS or AdV-Cas9 vector grew 322 over time, reaching an average size of more than 2000 mm 3 28 days after treatment ( Figure 4A) . 323 vector and PBS-treated mice implanted with H2228 cells containing the wild-type KRAS allele 325 ( Figure 4B ). It confirmed the high specificity of KRAS G12S targeting in vivo. The tumor weight was 326 also significantly decreased by 30% in animals treated with AdV-Cas9-sgG12S, compared to control 327 groups treated with either AdV-Cas9 vector or PBS (P<0.05) in A549 bearing mice ( Figure 4C) . 328
Consistent with tumor volume, there was no difference in tumor weight of H2228-implanted 329 groups ( Figure 4D) . 330
To examine the efficacy of repressing G12S transcription by dCas9-KRAB system in vivo, NSG mice 331 were xenografted with A549 and H2228 cells, and treated with dCas9-KRAB-sgG12S, non-targeting 332 virus, or PBS when tumor size reached a volume of 100-200 mm 3 ( Figure 4E-H) . The mice 333 xenografted with A549 cells and treated with dCas9-KRAB-sgG12S showed 15.6% (P<0.05) 334 decrease in tumor volume compared to a control ( Figure 4E ) and exhibited no notable metastasis 335 or mortality during the observation period of 28 days. In contrast, the mice xenografted with H2228 336 cells treated with dCas9-KRAB-sgG12S did not show any inhibition of tumor growth but instead 337 experienced a quick increase in tumor volume ( Figure 4F ). Similar rate of increase in tumor size 338 also observed in mice treated with non-targeting vector or PBS. Tumor weights were also measured 339 in mice treated with different viruses (Figure 4G, 4H) . A significant decrease of tumor weight (28.2%, 340 P<0.05) was observed in dCas9-KRAB-sgG12S treated mice xenografted with A549 cells ( Figure 4G) . 341
In contrast, the H2228-bearing mice injected with either dCas9-KRAB-sgG12S, non-targeting vector 342 or PBS treatment ( Figure 4H ) had little affected. 343
Throughout the mice study of gene-editing and transcription-repressing systems, no sign of 344 weight loss (Additional file 1: Figure S3A -S3D) was observed. Taken together, these in vivo data 345 suggested that gene targeting of mutant KRAS by SpCas9-sgG12S and dCas9-KRAB-sgG12S is effective and only restricted to the tumors with the KRAS mutations, with no obvious effects on 347 the other cell types. Besides, CRISPR/Cas9 genome-editing system targeting mutant KRAS is more 348 effective compared with the dCas9-KRAB mRNA-regulating system. 349 protein was not dramatically changed in AdV-Cas9 or AdV-Cas9-sgG12S treated groups ( Figure 5A) . 359
Disruption of KRAS-G12S significantly inhibited the
Consistently, dCas9-KRAB-sgG12S, but not V2 treated tumor tissues, exhibited markedly lower 360 levels of both total and mutant KRAS proteins in A549-engrafted mice ( Figure 5B ). Importantly, 361 tumor tissues from A549-engrafted mice treated with AdV-Cas9-sgG12S and dCas9-KRAB-sgG12S 362 both showed significant reduction of KRAS G12S protein through in situ IHC staining, but such 363 decrease was not observed in the control groups ( Figure 5C, 5D ). It implied that CRISPR/Cas9 364 system can efficiently target and reduce KRAS mutant protein expression. Taken together, these 365 data indicate that the application of both the gene-cutting CRISPR-Cas9 and mRNA-regulating 366 dCas9-KRAB systems could affect KRAS G12S protein downregulation in vivo and further result in a 23 results are consistent with in vivo data that tumor growth inhibition was not observed in AdV-Cas9-454 sgG12S treated H2228 tumors, demonstrating the specificity of CRISPR/Cas9 for targeting a mutant 455 allele that is in the seed sequence. The finding was in line with the previous report by Cong et al. 16 . 456 In another study, CRISPR/Cas9 was used to target a mutant allele where the single nucleotide 457 mutation generates a 5'-NGG-3' PAM sequence that WT allele did not have, thus enabling specific 458 targeting of mutant allele by Cas9 nuclease 18 . To extend this strategy to other cancer-driven 459 mutations that, either locate in seed sequence or generate PAM sequences recognized by SpCas9 460 or other Cas9 variants, we chose top 20 mutated genes and analyzed whether their mutations 461 could be targeted by SpCas9, SaCas9 and LbCpf1, by analyzing the seed region and PAM sequence 462 ( Figure 6E , 6F, Additional file 1: S4). We found that PAM sequence of CRISPR nucleases, especially 463 for SpCas9 and SaCas9, are widely distributed around the mutated sites. The results indicate that 464 this approach could be widely used to target other oncogenic mutations and could also be applied 465 to other Cas9 families or variants. Furthermore, this approach could be utilized for multiple gene 466 editing in cancers which are frequently characterized by mutation heterogeneity, and to test 467 functional relevance of tumor mutations employing CRISPR/Cas9 40,41 . 468 In contrast to the two previous studies 20,22 , we also assessed the off-target effects in vitro (Figure  469 3A, 3B) and found there were low off-target effects during our gene targeting. Besides, we found 470 the related mechanisms that disruption of KRAS G12S allele leads to blockade of AKT and ERK 471 signaling pathways that was confirmed by WB results, thus inhibiting tumor growth. Furthermore, 472
we assessed both the non-cutting system dCas9-KRAB and Cas9-sgG12S cleaving system and found 473 that the transcription repression system is also capable to inhibit tumor growth both in vitro and 474 in vivo, but at a lower efficiency. Given that dCas9-KRAB-sgG12S treatment only lead to transient gene, the continuous growth inhibition of proliferating tumor cells may not be achieved completely 477 using dCas9-KRAB-sgG12S. From this angle, the genome-editing CRISPR/Cas9 system is more 478 practical to eliminate KRAS activation persistently. Based on our data, this mutation-sgRNA 479 designing strategy is capable to distinguish the mutant allele from WT one at the resolution of 480 single nucleotide differences, thus enables KRAS mutation-targeting at a high specificity, which is 481 also beneficial to treat a broad spectrum of oncogenic mutations. Among thousands of mutations 482 of the top 20 cancer driver genes we surveyed, above 50% mutations of ten genes have potential 483 to be targeted by CRISPR system through our bioinformatic analysis. Not every oncogenic mutation 484
can be specifically targeted due to the lack of PAM sequence, and our bioinformatic pipeline 485 provides an easy, efficient, and high-throughput way to predict the editable sites. 486
Conclusions 487
In conclusion, we systematically demonstrated gene-editing and mRNA-regulating systems 488 targeted KRAS G12S mutant allele specifically and both in vitro tumor cell proliferation and in vivo 489 tumor growth were inhibited. In addition, bioinformatic analysis of 31555 SNP oncogenic 490 mutations provided a pipeline to analyze the distribution of PAM sequence for editing targets 491 screening. 492 in the sense strand of oncogenic mutations. Only when the mutation occurs in the seed sequence 717 or PAM sequence, it can be specifically targeted. But if the mutation occurs in the N of PAM NGG 718 sequence, it can't be targeted specifically. This situation is considered meaningless. M, mutation, 719 in red. Green arrow, the direction of PAM shift. Bottom, appearance of SpCas9 PAM sequence in 720 the anti-sense strand of oncogenic mutations. b PAM analysis of SaCas9 in the sense and anti-sense 721 strands of oncogenic mutations. PAM sequence of SaCas9 is NGRRN, if the mutation occurs at any 722 N of the PAM sequence, this situation is meaningless. M, mutation, in red. Green arrow, the 723 direction of PAM shift. c PAM analysis of LbCpf1 in the sense and anti-sense strands of oncogenic 724 mutations. PAM sequence of LbCpf1 is TTTV, V is all but T. If the original V is T, then the mutation 725 of V could lead to the specific targeting. M, mutation, in red. Green arrow, the direction of PAM
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